Loading...

Kelly CRISPR & Gene Editing Technology ETF

XDNA•NASDAQ
Financial Services
Asset Management
$7.38
$-0.12(-1.60%)

Kelly CRISPR & Gene Editing Technology ETF (XDNA) Stock Overview

Explore Kelly CRISPR & Gene Editing Technology ETF’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 69.2/100

Key Financials

Market Cap2.6M
P/E RatioN/A
EPS (TTM)N/A
ROE0.00%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$3.49

XDNA Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Kelly CRISPR & Gene Editing Technology ETF (XDNA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $3.49.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of N/A and a market capitalization of 2.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;